Specificity of antibody-dependent cellular cytotoxicity in sera from human immunodeficiency virus type 2-infected individuals. 1993

A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
Department of Virology Karolinska Institute, Stockholm, Sweden.

ADCC activity in sera from HIV-2-infected individuals was monitored against HIV-1IIIB, SIVmac, and three different HIV-2 strains. The sera mediated ADCC against the HIV-2 strains in high frequencies and reacted equally well with SIVmac, whereas no cross-reactivity was seen against HIV-1IIIB. The degree of antigenic similarities between the virus strains was also evaluated in order to estimate the variability of ADCC target regions. The SIVmac strain and two of the HIV-2 strains were antigenically more similar to each other whereas another HIV-2 strain appeared more distantly related with regard to ADCC target regions. Although strain-specific ADCC was present in some HIV-2-positive sera, HIV-2 ADCC was more broadly reactive and appeared in higher frequencies against these specific strains than has been previously shown for HIV-1 ADCC in a group of four HIV-1 strains. The difference was, however, not significant. To further delineate target regions for ADCC the sera were tested against peptides representing different regions of the HIV-2 envelope protein. The V3 region and the C-terminal end of gp125 were thus suggested to be involved in ADCC. Target regions for HIV-2-specific ADCC may only partly overlap with HIV-2-neutralizing regions since the two activities were not always present in the same sera. Characterization of broadly reacting immune responses like HIV-2-specific ADCC and identification of their specific target epitopes is essential for the development of an efficient AIDS vaccine.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian
D015488 HIV Antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
July 2013, Current HIV research,
A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
February 1989, Journal of virology,
A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
October 1999, The Journal of infectious diseases,
A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
February 1987, Journal of immunology (Baltimore, Md. : 1950),
A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
November 1996, The Journal of infectious diseases,
A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
January 2009, Journal of virology,
A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
January 1989, Journal of acquired immune deficiency syndromes,
A Von Gegerfelt, and C Diaz-Pohl, and E M Fenyö, and K Broliden
February 2002, The Journal of infectious diseases,
Copied contents to your clipboard!